The High Mobility Group Protein B1 pipeline drugs market research report outlays comprehensive information on the High Mobility Group Protein B1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the High Mobility Group Protein B1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

The report also covers products from therapy areas such as Gastrointestinal, Infectious Disease, Oncology, and Cardiovascular which include the indications Metabolic Dysfunction-Associated Steatohepatitis (MASH), Acute Liver Failure, Sepsis, Influenzavirus A Infections, Solid Tumor, Glioblastoma Multiforme (GBM), Cerebral Infarction (Brain Infarction), and Ischemic Cardiomyopathy. It also reviews key players involved in High Mobility Group Protein B1 targeted therapeutics development with respective active and dormant or discontinued products.

The High Mobility Group Protein B1 pipeline targets constitutes close to 13 molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 5, and 2 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 3, and 1 molecule.

High Mobility Group Protein B1 overview

High mobility group box 1 protein also known as high-mobility group protein 1 (HMG-1) is a protein encoded by the HMGB1 gene.HMGB1 is secreted by immune cells like macrophages, monocytes and dendritic cells through leaderless secretory pathway. Activated macrophages and monocytes secrete HMGB1. The mechanism of inflammation and damage is binding to TLR4, which mediates HMGB1-dependent activation of macrophage cytokine release. Treatment includes antibodies that neutralize HMGB1 protects against damage and tissue injury during arthritis, colitis, ischemia, sepsis, endotoxemia, and systemic lupus erythematosus.

For a complete picture of High Mobility Group Protein B1’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.